- Page 1 and 2: Tuberculosis Interventions Interven
- Page 3 and 4: Editor International Union Against
- Page 5 and 6: Isoniazid plus rifampicin plus pyra
- Page 7 and 8: 4. Preventive chemotherapy . . . .
- Page 12 and 13: Preface This monograph adds a modul
- Page 14 and 15: Introduction The aim of interventio
- Page 16 and 17: prophylactic treatment of special p
- Page 18 and 19: Chemotherapy Summary - the role of
- Page 20 and 21: two-week to one-month daily phase.
- Page 22: tratively easiest, and also of leas
- Page 25 and 26: standard summary of the major aspec
- Page 27 and 28: Laboratories in Switzerland / Unite
- Page 29 and 30: drug target (inhA). However, the me
- Page 31 and 32: tant. Isoniazid also has excellent
- Page 33 and 34: fibrotic lesions, 123 the risk of h
- Page 35 and 36: • anti-coagulants such as warfari
- Page 37 and 38: ifampicin, a peak level of 12 to 14
- Page 39 and 40: obtained six hours after administra
- Page 41 and 42: Table 3. Summary of adverse reactio
- Page 43 and 44: • anti-asthmatics such as theophy
- Page 45 and 46: Pharmacokinetics. After oral intake
- Page 47 and 48: � � � � � � � � �
- Page 49 and 50: Table 5. Summary of adverse reactio
- Page 51 and 52: ����� ���� ��
- Page 53 and 54: ney function is impaired, the dosag
- Page 55 and 56: depending on the technique of susce
- Page 57 and 58: ��������� ��
- Page 59 and 60:
Table 8. Fixed-dose combinations (F
- Page 61 and 62:
��� ��� �� � �
- Page 63 and 64:
��� ���� �� �
- Page 65 and 66:
found in caseous foci did not excee
- Page 67 and 68:
������ �� ���
- Page 69 and 70:
Number of viable bacilli Mutants re
- Page 71 and 72:
Council, streptomycin monotherapy,
- Page 73 and 74:
Per cent culture positive 100 90 80
- Page 75 and 76:
Thioacetazone replaced para-aminosa
- Page 77 and 78:
makes it impossible to reduce the m
- Page 79 and 80:
Not all drugs are equally suitable
- Page 81 and 82:
In a third prospective study in the
- Page 83 and 84:
Based on these pharmacokinetic prop
- Page 85 and 86:
that the sputum bacillary load may
- Page 87 and 88:
ment regimen is efficacious and not
- Page 89 and 90:
Many countries have moved towards a
- Page 91 and 92:
to the medications used in patients
- Page 93 and 94:
Case holding Prescription of an ade
- Page 95 and 96:
Strains resistant to isoniazid alon
- Page 97 and 98:
The patient is maintained on these
- Page 99 and 100:
pyrazinamide. Cutaneous adverse dru
- Page 101 and 102:
with ethambutol plus streptomycin u
- Page 104 and 105:
2. Prophylactic treatment In this m
- Page 106 and 107:
Early vaccine development 3. Vaccin
- Page 108 and 109:
Following these early experiments i
- Page 110 and 111:
Petroff’s concerns about a revers
- Page 112 and 113:
In a prospective study in South Afr
- Page 114 and 115:
etrospectively, such as in case-con
- Page 116 and 117:
Prospective and retrospective studi
- Page 118 and 119:
��� ����� ���
- Page 120 and 121:
Protection conferred by BCG vaccina
- Page 122 and 123:
Ulleval England South Africa Madana
- Page 124 and 125:
Haiti N. Am. Indians Madanapelle Mu
- Page 126 and 127:
Differences in vaccine strains The
- Page 128 and 129:
Differences in prevalence of infect
- Page 130 and 131:
Incidence per 10,000 70 60 50 40 30
- Page 132 and 133:
BCG re-vaccination It is or has bee
- Page 134 and 135:
Number of cases 30 20 10 0 Gothenbu
- Page 136 and 137:
4. Preventive chemotherapy In the e
- Page 138 and 139:
Tuberculosis was much more frequent
- Page 140 and 141:
arracks. 878 On entering service in
- Page 142 and 143:
�����������
- Page 144 and 145:
A large trial was conducted in Euro
- Page 146 and 147:
evidence was the trial of the Inter
- Page 148 and 149:
ment, mice were assigned to five gr
- Page 150 and 151:
� �� � ���� ��
- Page 152 and 153:
thus suggested equivalence (the hyp
- Page 154 and 155:
��� ���� �� �
- Page 156 and 157:
Appendix 1 Adjunctive treatment Adj
- Page 158 and 159:
had a more rapid decrease in perica
- Page 160 and 161:
ment of pulmonary tuberculosis. 679
- Page 162 and 163:
Numerous drugs other than the first
- Page 164 and 165:
Similar to aminoglycosides, capreom
- Page 166 and 167:
activity in experimental models. 25
- Page 168 and 169:
Rifabutin is active against a wide
- Page 170 and 171:
Adverse drug events similar to thos
- Page 172 and 173:
Clarithromycin Erythromycin, the pr
- Page 174:
ial agents was thus only natural. 1
- Page 177 and 178:
However, an effect is difficult to
- Page 180 and 181:
References 1. Rieder HL. Epidemiolo
- Page 182 and 183:
29. Brooks SM, Lassiter NL, Young E
- Page 184 and 185:
59. Sarma GR, Kailasam S, Nair NGK,
- Page 186 and 187:
96. Asai S, Shimoda T, Hara K, Fuji
- Page 188 and 189:
129. Hauser MJ, Baier H. 1982; 16:
- Page 190 and 191:
165. Ahn HC, Yang JH, Lee HB, Rhee
- Page 192 and 193:
199. Burke M, Logan J. Hepatic dysf
- Page 194 and 195:
230. Morgan JR, Clarke KW, Brear SG
- Page 196 and 197:
266. Ridtitid W, Wongnawa M, Mahatt
- Page 198 and 199:
296. Brodie MJ, Boobis AR, Hillyard
- Page 200 and 201:
326. Kannapiran M, Krishnamurthy PV
- Page 202 and 203:
357. Carr DE, Henkind P. Ocular man
- Page 204 and 205:
392. Feldman WH, Hinshaw HC. Effect
- Page 206 and 207:
426. Mitchison DA. Natural sensitiv
- Page 208 and 209:
456. Mitchison DA. The action of an
- Page 210 and 211:
487. Newman R, Doster B, Murray FJ,
- Page 212 and 213:
514. British Thoracic Association.
- Page 214 and 215:
541. Konstam PG, Konstam ST. Spinal
- Page 216 and 217:
563. Ellard GA, Humphries MJ, Allen
- Page 218 and 219:
593. Hawken M, Nunn P, Gathua S, Br
- Page 220 and 221:
619. World Health Organization. The
- Page 222 and 223:
644. Sandman L, Schluger NW, Davido
- Page 224 and 225:
680. Lange L. Zu den Tuberkulosesch
- Page 226 and 227:
710. Ninane J, Grymonprez A, Burton
- Page 228 and 229:
741. Aronson JD. Protective vaccina
- Page 230 and 231:
771. D’Arcy Hart P, Pollock TM, S
- Page 232 and 233:
800. Middlebrook G, Cohn ML. Some o
- Page 234 and 235:
828. Orme I, Collins FM. Efficacy o
- Page 236 and 237:
856. Elliott AM, Nakiyingi J, Quigl
- Page 238 and 239:
885. Mwinga A, Hosp M, Godfrey-Faus
- Page 240 and 241:
910. Research Committee of the Tube
- Page 242 and 243:
940. Rooney JJ, Crocco JA, Lyons HA
- Page 244 and 245:
973. Iseman MD, Madsen L, Goble M,
- Page 246 and 247:
1006. Freerksen E, Krüger-Thiemer
- Page 248 and 249:
1038. Akhtar AJ, Crompton GK, Schon
- Page 250 and 251:
1067. Kohno S, Koga H, Kaku M, Maes
- Page 252 and 253:
1095. Yang B, Koga H, Ohno H, Ogawa
- Page 254 and 255:
1125. Kwon HH, Tomioka H, Saito H.
- Page 256 and 257:
1152. Suzuki K, Tsuyuguchi K, Matsu
- Page 258 and 259:
1178. Amaral L, Kristiansen JE, Viv
- Page 260:
1207. Zhu X, Venkataprasad N, Ivany
- Page 264:
IMPRIMÉ EN FRANCE